The challenge of drug-rechallenge: Facts and controversies

Clinics in Dermatology

Volumn 28, Issue 3, 2010, Pages 349-353

  Davidovici, Batya B ^a   Wolf, Ronni ^a  

^a KAPLAN MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMINOPENICILLIN; ANTICONVULSIVE AGENT; ANTIMALARIAL AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CEFACLOR; DAPSONE; DIGOXIN; GOLD; LIDOCAINE; LITHIUM; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PENICILLIN G; PREDNISONE; PROPYLTHIOURACIL; STEROID; THIAZIDE DIURETIC AGENT; PRESCRIPTION DRUG;

ACNE LIKE DISEASE; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC VALUE; DRUG CONTRAINDICATION; DRUG ERUPTION; DRUG IDENTIFICATION; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; LABORATORY TEST; LICHEN PLANUS LIKE DISEASE; PEMPHIGUS; PREDICTION; PRIORITY JOURNAL; PROVOCATION TEST; PSEUDOLYMPHOMA; PSORIASIS; RELIABILITY; RISK BENEFIT ANALYSIS; SERUM SICKNESS LIKE DISEASE; SKIN MANIFESTATION; SKIN TEST; VASCULITIS; DRUG ERUPTIONS; PREDICTIVE VALUE; RISK ASSESSMENT;

DRUG ERUPTIONS; HUMANS; PREDICTIVE VALUE OF TESTS; PRESCRIPTION DRUGS; RISK ASSESSMENT;

EID: 77953570618     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2009.06.019     Document Type: Article

References (37)

1. Hallas J., Harvald B., Gram L.F., et al. Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med 1990, 228:83-90.
2. Einarson T.R. Drug-related hospital admissions. Ann Pharmacother 1993, 27:832-840.
3. Lazarou J., Pomeranz B., Corey P. Incidence of adverse reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998, 279:1200-1205.
4. Impicciatore P., Choonara I., Clarkson A., Provasi D., Pandolfini C., Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 2001, 52:77-83.
5. Naldi L., Conforti A., Venegoni M., et al. Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol 1999, 48:839-846.
6. Bigby M., Jick S., Jick H., Arndt K. Drug-induced cutaneous reactions: a report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 1986, 256:3358-3363.
7. Alanko K., Stubb S., Kauppinen K. Cutaneous drug reactions: clinical types and causative agents. A five-year survey of in-patients (1981-1985). Acta Derm Venereol 1989, 69:223-226.
8. Ives T., Bentz E., Gwyther R. Dermatologic adverse drug reactions in a family medicine setting. Arch Fam Med 1992, 1:241-245.
9. Roujeau J.C., Stern R.S. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994, 331:1272-1285.
10. Ibia E.O., Schwartz R.H., Wiedermann B.L. Antibiotic rashes in children: a survey in a private practice setting. Arch Dermatol 2000, 136:849-854.
11. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol 2001, 137:765-770.
12. Valeyrie-Allanore L., Sassolas B., Roujeau J.C. Drug-induced skin, nail and hair disorders. Drug Saf 2007, 30:1011-1030.
13. Manders S.M. Serious and life-threatening drug eruptions. Am Fam Physician 1995, 51:1865-1872.
14. Nigen S., Knowles S.R., Shear N.H. Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol 2003, 2:278-299.
15. Arndt K.A., Jick H. Rates of cutaneous reactions to drugs. A report from the Boston Collaborative Drug Surveillance Program. JAMA 1976, 235:918-923.
16. Food and Drug Administration Guideline for adverse experience reporting for licensed biological products: definitions Available at:. http://www.fda.gov/medwatch/report/cberguid/define.htm.
17. Begaud B. Standardized assessment of adverse drug reactions: the method used in France. Special workshop-clinical. Drug Inf J 1984, 18:275-281.
18. Demoly P., Michel F.B., Bousquet J. In vivo methods for study of allergy: skin tests, techniques and interpretation. Allergy, principles and practice 1998, 430-439. Mosby Co, New York. 5th ed. E. Middleton, C.E. Reed, E.F. Ellis, N.F. Adkinson, J.W. Yunginger (Eds.).
19. Demoly P., Bousquet J. Epidemiology of drug allergy. Curr Opin Allergy Clin Immunol 2001, 1:305-310.
20. Ring J., Brockow K. Adverse drug reactions: Mechanisms and assessment. Eur Surg Res 2002, 34:170-175.
21. Vieluf D., Przybilla B., Schwerbrock U., Ring J. Oral provocation test in the diagnosis of anaphylactoid reactions to "mild" analgesic preparations. Int Arch Allergy Immunol 1995, 107:268-271.
22. Bernstein I.L., Gruchalla R.S., Lee R.E., Nicklas R.A., Dykewicz M.S. Disease management of drug hypersensitivity: a practice parameter. Ann Allergy Asthma Immunol 1999, 83:665-700.
23. Memorandum SIAIC sulla diagnosi di allergia/intolleranza a farmaci. Giornale Ital Allergol Immunol Clin 1998, 8:573-575. SIAIC (Societa Italiana di Allergologia ed Immunologia Clinica).
24. Gruchalla R.S. Clinical assessment of drug-induced disease. Lancet 2000, 28:1505-1511.
25. de Weck A.L. Penicillins and cephalosporins. Handbook of experimental pharmacology 1983, Vol. 63:423-482. Springer Verlag, Berlin. A. de Weck, H. Bundgaard (Eds.).
26. Li Wan Po A., Kendall M.J. Causality assessment of adverse effects. When is re-challenge ethically acceptable. Drug Safety 2001, 24:793-799.
27. Romano A., Quaratino D., Di Fonso M., Papa G., Venuti A., Gasbarrini G. A diagnostic protocol for evaluation nonimmediate reactions to aminopenicillins. J Allergy Clin Immunol 1999, 103:1186-1190.
28. Gleckman R.A., Borrego F. Adverse reactions to antibiotics. Postgrad Med 1997, 101:97-108.
29. Wolkenstein P., Revuz J. Drug-induced severe skin reactions. Drug Safety 1995, 13:56-68.
30. Kanwar A.J., Bharija S.C., Belhaj M.S. Fixed drug eruptions in children: a series of 23 cases with provocative tests. Dermatologica 1986, 172:315-320.
31. Kauppinen K., Stubb S. Fixed eruptions-causative drugs and challenge tests. Br J Dermatol 1985, 112:575-578.
32. Solensky R., Earl H.S., Gruchalla R.S. Lack of penicillin resensitization in patients with a history of penicillin allergy after receiving repeated penicillin courses. Arch Int Med 2002, 162:822-826.
33. Girard M. Conclusiveness of rechallenge in the interpretation of adverse drug reactions. Br J Clin Pharmacol 1987, 23:73-79.
34. Hein U.R., Chantraine-Hess S., Worm M., Zuberbier T., Henz B.M. Evaluation of systemic provocation tests in patients with suspected allergic and pseudoallergic drug reactions. Acta Derm Venereol 1999, 79:139-142.
35. Calhoun W.J., Dick E.C., Schwartz L.B., Busse W.W. A common cold virus, rhinovirus 16, potentiates airway inflammation after segmental antigen bronchoprovocation in allergic subjects. J Clin Invest 1994, 94:2200-2208.
36. Barbaud A., Goncalo M., Bruynzeel D., Bircher A. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001, 45:321-328.
37. Reidenberg M.M., Lowenthal D.T. Adverse nondrug reactions. N Engl J Med 1968, 279:678-679.